Fig. 2

Ferroptosis inducers promoted cuproptosis in liver cancer cells A. MHCC-97 H cells were treated with indicated drugs for 24 h (DMSO, 10µM erastin (Era), 10µM sorafenib (Sora), 10nM elesclomol (ES), 10µM Era + 10nM ES, 10µM Sora + 10nM ES), DLAT protein aggregation was analyzed by immunofluorescence (IF) (green, DLAT; red, Mitotracker; blue, DAPI). White scale bars on full tiled images are 5μm B and C. The distribution of DLAT protein in soluble or insoluble fraction after treatment with indicated drugs for 24 h (DMSO, 10nM ES, 10µM Sora (or 10µM Era) + 10nM ES) was detected by western blotting in MHCC-97 H cells D and E. MHCC-97 H cells were transiently transfected with siFDX1, siNC was used as negative control, then the transfected cells were treated with sorafenib (Sora) or erastin (Era) and Elesclomol (ES) for another 48 h before cell viability was measured with CCK-8 assay F and G. MHCC-97 H cells were transiently transfected with siLIAS, siNC was used as negative control, then the transfected cells were treated with sorafenib (Sora) or erastin (Era) and Elesclomol (ES) for another 48 h before cell viability was measured with CCK-8 assay. For A to G, media were supplemented with 1µM CuCl₂